Amanote Research
Register
Sign In
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Brutons Tyrosine Kinase
doi 10.1021/acs.jmedchem.9b00687.s001
Full Text
Open PDF
Abstract
Available in
full text
Date
Unknown
Authors
Unknown
Publisher
American Chemical Society (ACS)
Related search
The BTK Inhibitor Zanubrutinib (BGB-3111) Demonstrated Synergies With Other Anti-Lymphoma Targeted Agents
Haematologica
Hematology
Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase With Potent Antimelanoma Activity
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Bruton's Tyrosine Kinase (Btk) Inhibitor BGB-3111 Demonstrates High Very Good Partial Response (Vgpr) Rate in Patients With Waldenström Macroglobulinemia (Wm)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
P2.13-32 TAK-788 Is a Novel and Potent Tyrosine Kinase Inhibitor With Selective Activity Against EGFR/HER2
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
TAS0728, a Covalent-Binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models
Molecular Cancer Therapeutics
Cancer Research
Oncology
BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers
Molecular Cancer Therapeutics
Cancer Research
Oncology
Discovery of WAY-260022, a Potent and Selective Inhibitor of the Norepinephrine Transporter
ACS Medicinal Chemistry Letters
Organic Chemistry
Biochemistry
Drug Discovery
Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor
Journal of Clinical Pharmacology
Pharmacology
Characterization of GSK′963: A Structurally Distinct, Potent and Selective Inhibitor of RIP1 Kinase
Cell Death Discovery
Cancer Research
Molecular Neuroscience
Immunology
Cell Biology
Cellular
